Skip to content

Author

Haifeng Liu

We have 3 of 20 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Anlotinib suppresses homologous recombination via the E2F8-RAD51 axis to activate STING immunity and potentiate PARP inhibitor synthetic lethality in resistant small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy that almost invariably acquires resistance to first-line platinum-based chemotherapy, leading to early relapse. PARP inhibitors (PARPi) hold theoretical potential for SCLC due to universal TP53/RB1 deletion, but their monotherapy activity has...

Wen-Jun Shao, Pei-Yan Zhao, Yang Tan et al. · 0 citations
Review Oct 2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

BACKGROUND Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...

Chong-Rui Xu, Yan Zhang, G. Lin et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.